Advertisement

Clinical Pharmacokinetics

, Volume 56, Issue 8, pp 815–823 | Cite as

Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders

  • Elisabeth I. MinderEmail author
  • Jasmin Barman-Aksoezen
  • Xiaoye Schneider-Yin
Review Article

Abstract

Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor (MC1R), and MC1R signaling increases melanin synthesis, induces antioxidant activities, enhances DNA repair processes and modulates inflammation. The loss-of-function variants of the MC1R present in fair-skinned Caucasians are less effectively activated by the natural hormone. Afamelanotide was the first α-MSH analogue to be applied to human volunteers. Ten daily doses of between 0.08 and 0.21 mg/kg in saline injected subcutaneously resulted in long-lasting skin pigmentation and enabled basic pharmacokinetics. Subcutaneous application had full bioavailability, but neither oral nor transdermal application resulted in measurable plasma concentrations or pigmentation response. Two trials in human volunteers showed that neither MC1R variants nor fair skin reduced the afamelanotide-induced increase in skin pigmentation. A controlled-release formulation optimizes administration in man and is effective at a lower dose than the daily saline injections. Promising therapeutic results were published in polymorphic light eruption, erythropoietic protoporphyria (EPP), solar urticaria, Hailey–Hailey disease and vitiligo. In 2014, afamelanotide was approved by the European Medicines Agency for the prevention of phototoxicity in adult patients with EPP. No late effects were reported in volunteers 25 years after the first exposure or after continuous long-term application of up to 8 years in EPP patients, and an immunogenic potential has been excluded. Generally, adverse effects were benign in all trials.

Keywords

Vitiligo Omalizumab Skin Type Dermatological Life Quality Index MC1R Variant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Compliance with Ethical Standards

Funding

Elisabeth I. Minder, Jasmin Barman-Aksoezen and Xiaoye Schneider-Yin were partly supported by grants from the Foundation for Scientific Research of Triemli Hospital, the Foundation for Scientific Research of the University of Zurich, the Hartmann–Müller Foundation, and the Velux Foundation. The immunogenicity studies were partly supported by a grant from Clinuvel Pharmaceutical, Melbourne, VIC, Australia.

Conflict of interest

Elisabeth Minder was the principal investigator of two trials of afamelanotide by Clinuvel Pharmaceutical, Melbourne, VIC, Australia. Jasmin Barman-Aksoezen and Xiaoye Schneider-Yin declare that they have no conflicts of interest that might be relevant to the contents of this article.

References

  1. 1.
    Malagoli D, Accorsi A, Ottaviani E. The evolution of pro-opiomelanocortin: looking for the invertebrate fingerprints. Peptides. 2011;32:2137–40.CrossRefPubMedGoogle Scholar
  2. 2.
    Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell. 2007;128:853–64.CrossRefPubMedGoogle Scholar
  3. 3.
    Aroca P, Urabe K, Kobayashi T, Tsukamoto K, Hearing VJ. Melanin biosynthesis patterns following hormonal stimulation. J Biol Chem. 1993;268:25650–5.PubMedGoogle Scholar
  4. 4.
    del Marmol V, Beermann F. Tyrosinase and related proteins in mammalian pigmentation. FEBS Lett. 1996;381:165–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Gibbs S, Murli S, De BG, Mulder A, Mommaas AM, Ponec M. Melanosome capping of keratinocytes in pigmented reconstructed epidermis: effect of ultraviolet radiation and 3-isobutyl-1-methyl-xanthine on melanogenesis. Pigment Cell Res. 2000;13:458–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Kauser S, Thody AJ, Schallreuter KU, Gummer CL, Tobin DJ. A fully functional proopiomelanocortin/melanocortin-1 receptor system regulates the differentiation of human scalp hair follicle melanocytes. Endocrinology. 2005;146:532–43.CrossRefPubMedGoogle Scholar
  7. 7.
    Osawa M, Egawa G, Mak SS, Moriyama M, Freter R, Yonetani S, et al. Molecular characterization of melanocyte stem cells in their niche. Development. 2005;132:5589–99.CrossRefPubMedGoogle Scholar
  8. 8.
    Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29:581–602.CrossRefPubMedGoogle Scholar
  9. 9.
    Kokot A, Metze D, Mouchet N, Galibert MD, Schiller M, Luger TA, et al. Alpha-melanocyte-stimulating hormone counteracts the suppressive effect of UVB on Nrf2 and Nrf-dependent gene expression in human skin. Endocrinology. 2009;150:3197–206.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Bohm M, Luger TA, Tobin DJ, Garcia-Borron JC. Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology. J Invest Dermatol. 2006;126:1966–75.CrossRefPubMedGoogle Scholar
  11. 11.
    Abdel-Malek ZA, Ruwe A, Kavanagh-Starner R, Kadekaro AL, Swope V, Haskell-Luevano C, et al. alpha-MSH tripeptide analogs activate the melanocortin 1 receptor and reduce UV-induced DNA damage in human melanocytes. Pigment Cell Melanoma Res. 2009;22:635–44.CrossRefPubMedGoogle Scholar
  12. 12.
    Bennett DC, Medrano EE. Molecular regulation of melanocyte senescence. Pigment Cell Res. 2002;15:242–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27:921–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Jiang J, Sharma SD, Nakamura S, Lai JY, Fink JL, Hruby VJ, et al. The melanotropic peptide, [Nle4, D-Phe7] alpha-MSH, stimulates human melanoma tyrosinase activity and inhibits cell proliferation. Pigment Cell Res. 1995;8:314–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Eves P, Haycock J, Layton C, Wagner M, Kemp H, Szabo M, et al. Anti-inflammatory and anti-invasive effects of alpha-melanocyte-stimulating hormone in human melanoma cells. Br J Cancer. 2003;89:2004–15.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zhu N, Eves PC, Katerinaki E, Szabo M, Morandini R, Ghanem G, et al. Melanoma cell attachment, invasion, and integrin expression is upregulated by tumor necrosis factor alpha and suppressed by alpha melanocyte stimulating hormone. J Invest Dermatol. 2002;119:1165–71.CrossRefPubMedGoogle Scholar
  17. 17.
    Cone RD. Studies on the physiological functions of the melanocortin system. Endocr Rev. 2006;27:736–49.CrossRefPubMedGoogle Scholar
  18. 18.
    Minder EI. Afamelanotide, an agonistic analog of alpha-melanocyte-stimulating hormone, in dermal phototoxicity of erythropoietic protoporphyria. Expert Opin Investig Drugs. 2010;19:1591–602.CrossRefPubMedGoogle Scholar
  19. 19.
    Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, et al. 4-Norleucine, 7-d-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc Natl Acad Sci USA. 1980;77:5754–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hadley ME, Heward CB, Hruby VJ, Sawyer TK, Yang YC. Biological actions of melanocyte-stimulating hormone. Ciba Found Symp. 1981;81:244–62.PubMedGoogle Scholar
  21. 21.
    Dorr RT, Dawson BV, al-Obeidi F, Hadley ME, Levine N, Hruby VJ. Toxicologic studies of a superpotent alpha-melanotropin, [Nle4, D-Phe7]alpha-MSH. Invest New Drugs. 1988;6:251–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Dawson BV, Ford CA, Holloway H, Dorr RT, Johnson P. Administration of melanotropic peptides during gestation in the rodent. Toxicology. 1993;77:91–101.CrossRefPubMedGoogle Scholar
  23. 23.
    Castrucci AM, Hadley ME, Sawyer TK, Hruby VJ. Enzymological studies of melanotropins. Comp Biochem Physiol B. 1984;78:519–24.CrossRefPubMedGoogle Scholar
  24. 24.
    Peters EM, Tobin DJ, Seidah NG, Schallreuter KU. Pro-opiomelanocortin-related peptides, prohormone convertases 1 and 2 and the regulatory peptide 7B2 are present in melanosomes of human melanocytes. J Invest Dermatol. 2000;114:430–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Lerner AB, McGuire JS. Effect of alpha- and betamelanocyte stimulating hormones on the skin colour of man. Nature. 1961;189:176–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Levine N, Sheftel SN, Eytan T, Dorr RT, Hadley ME, Weinrach JC, et al. Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA. 1991;266:2730–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004;140:827–35.CrossRefPubMedGoogle Scholar
  28. 28.
    Newton RA, Smit SE, Barnes CC, Pedley J, Parsons PG, Sturm RA. Activation of the cAMP pathway by variant human MC1R alleles expressed in HEK and in melanoma cells1. Peptides. 2005;26:1818–24.CrossRefPubMedGoogle Scholar
  29. 29.
    Frandberg PA, Muceniece R, Prusis P, Wikberg J, Chhajlani V. Evidence for alternate points of attachment for alpha-MSH and its stereoisomer [Nle4, D-Phe7]-alpha-MSH at the melanocortin-1 receptor. Biochem Biophys Res Commun. 1994;202:1266–71.CrossRefPubMedGoogle Scholar
  30. 30.
    Barnetson RS, Ooi TK, Zhuang L, Halliday GM, Reid CM, Walker PC, et al. [Nle4-D-Phe7]-alpha-melanocyte-stimulating hormone significantly increased pigmentation and decreased UV damage in fair-skinned Caucasian volunteers. J Invest Dermatol. 2006;126:1869–78.CrossRefPubMedGoogle Scholar
  31. 31.
    Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM. Effect of MELANOTAN, [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles. Peptides. 2006;27:388–94.CrossRefPubMedGoogle Scholar
  32. 32.
    Luger TA, Scholzen T, Grabbe S. The role of alpha-melanocyte-stimulating hormone in cutaneous biology. J Investig Dermatol Symp Proc. 1997;2:87–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest. 1997;99:1165–72.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Rajora N, Boccoli G, Catania A, Lipton JM. alpha-MSH modulates experimental inflammatory bowel disease. Peptides. 1997;18:381–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Dawson BV, Hadley ME, Levine N, Kreutzfeld KL, Don S, Eytan T, et al. In vitro transdermal delivery of a melanotropic peptide through human skin. J Invest Dermatol. 1990;94:432–5.CrossRefPubMedGoogle Scholar
  36. 36.
    Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, et al. Skin pigmentation and pharmacokinetics of melanotan-I in humans. Biopharm Drug Dispos. 1997;18:259–69.CrossRefPubMedGoogle Scholar
  37. 37.
    Bhardwaj R, Blanchard J. Controlled-release delivery system for the alpha-MSH analog melanotan-I using poloxamer 407. J Pharm Sci. 1996;85:915–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Bhardwaj R, Hadley ME, Dorr RT, Dvorakova K, Brooks C, Blanchard J. Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, melanotan-I. Pharm Res. 2000;17:593–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Bhardwaj R, Blanchard J. In vitro characterization and in vivo release profile of a poly (d, l-lactide-co-glycolide)-based implant delivery system for the alpha-MSH analog, melanotan-I. Int J Pharm. 1998;170:109–17.CrossRefGoogle Scholar
  40. 40.
    Harms J, Lautenschlager S, Minder CE, Minder EI. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med. 2009;360:306–7.CrossRefPubMedGoogle Scholar
  41. 41.
    Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373:48–59.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Fabrikant J, Touloei K, Brown SM. A review and update on melanocyte stimulating hormone therapy: afamelanotide. J Drugs Dermatol. 2013;12:775–9.PubMedGoogle Scholar
  43. 43.
    Haylett AK, Nie Z, Brownrigg M, Taylor R, Rhodes LE. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue [Nle4-D-Phe7]-alpha-MSH. Br J Dermatol. 2011;164:407–14.CrossRefPubMedGoogle Scholar
  44. 44.
    Biolcati G, Aurizi C, Barbieri L, Cialfi S, Screpanti I, Talora C. Efficacy of the melanocortin analogue Nle4-D-Phe7-alpha-melanocyte-stimulating hormone in the treatment of patients with Hailey–Hailey disease. Clin Exp Dermatol. 2014;39:168–75.CrossRefPubMedGoogle Scholar
  45. 45.
    Bohm M, Ehrchen J, Luger TA. Beneficial effects of the melanocortin analogue Nle4-D-Phe7-alpha-MSH in acne vulgaris. J Eur Acad Dermatol Venereol. 2014;28:108–11.CrossRefPubMedGoogle Scholar
  46. 46.
    Grimes PE, Hamzavi I, Lebwohl M, Ortonne JP, Lim HW. The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo. JAMA Dermatol. 2013;149:68–73.CrossRefPubMedGoogle Scholar
  47. 47.
    Jiang J. Microscopic visualization of melancyte/melanoma melanotropic receptors. Tucson: University of Arizona; 1993.Google Scholar
  48. 48.
    Smith E, Kiss F, Porter RM, Anstey AV. A review of UVA-mediated photosensitivity disorders. Photochem Photobiol Sci. 2012;11:199–206.CrossRefPubMedGoogle Scholar
  49. 49.
    Clinuvel Pharmaceuticals Limited. Clinuvel anounces PLE phase III preliminary results. Clinuvel Pharmaceuticals Ltd; 2009. http://www.clinuvel.com/2009-announcements/item/140-clinuvel-announces-ple-phase-iii-preliminary-results. Accessed 3 Jan 2017.
  50. 50.
    Schneider-Yin X, Minder EI. Erythropoietic protoporphyria and X-linked dominant protoporphyria. In: Ferreira GC, editor. Porphyrias and sideroblastic anemias. Vol. 29 of the handbook of porphyrin science: 299–328. Series edited by Kadish KM, Simth KM, Guilard R. Singapore: World Scientific Publishing Company; 2013.Google Scholar
  51. 51.
    Afonso SG, Enriquez DS, Batlle A. Photodynamic and light independent action of 8 to 2 carboxylic free porphyrins on some haem-enzymes. Int J Biochem Cell Biol. 2001;33:1208–14.CrossRefPubMedGoogle Scholar
  52. 52.
    Menon IA, Becker MA, Persad SD, Haberman HF. Quantitation of hydrogen peroxide formed during UV-visible irradiation of protoporphyrin, coproporphyrin and uroporphyrin. Clin Chim Acta. 1990;186:375–81.CrossRefPubMedGoogle Scholar
  53. 53.
    Lim HW. Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic protoporphyria. Immunol Ser. 1989;46:671–85.PubMedGoogle Scholar
  54. 54.
    Timonen K, Kariniemi AL, Niemi KM, Teppo AM, Tenhunen R, Kauppinen R. Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol. 2000;43:489–97.CrossRefPubMedGoogle Scholar
  55. 55.
    Minder EI, Schneider-Yin X, Steuer J, Bachmann LM. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand). 2009;55:84–97.Google Scholar
  56. 56.
    Minder EI, Harms J, Lautenschlager S, Schneider-Yin X, Deybach JC, Minder CE. A double-blind, randomized, controlled phase III trial of afamelanotide (an alpha-MSH analogue) in erythropoietic protoporphyria (EPP): preliminary data on a Swiss cohort of patients and a model to determine efficacy in EPP [abstract]. Berzelius Symposium 81: Porphyrins and Porphyrias. Stockholm: 2009.Google Scholar
  57. 57.
    Langendonk J, Karstens F, SiJbrands E, Hanneken S, Anstey A, Deybach J, et al. Afamelanotide implants effectively reduce pain and prolong sun-tolerance in patients with erythropoietic protoporphyria; results of a phase III, multicenter, double-blind, randomized, placebo-controlled trial. Clin Chem Lab Med. 2013;51:eA12.Google Scholar
  58. 58.
    Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172:1601–12.CrossRefPubMedGoogle Scholar
  59. 59.
    Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74–84.CrossRefPubMedGoogle Scholar
  60. 60.
    Lim HW, Grimes PE, Lebwohl M. Indications and limitations of afamelanotide for treating vitiligo-reply. JAMA Dermatol. 2015;151:350.CrossRefPubMedGoogle Scholar
  61. 61.
    Cialfi S, Oliviero C, Ceccarelli S, Marchese C, Barbieri L, Biolcati G, et al. Complex multipathways alterations and oxidative stress are associated with Hailey–Hailey disease. Br J Dermatol. 2010;162:518–26.CrossRefPubMedGoogle Scholar
  62. 62.
    Manca S, Magrelli A, Cialfi S, Lefort K, Ambra R, Alimandi M, et al. Oxidative stress activation of miR-125b is part of the molecular switch for Hailey–Hailey disease manifestation. Exp Dermatol. 2011;20:932–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Summary of product characteristics (afamelanotide/Scenesse). 2015.Google Scholar
  64. 64.
    Ong S, Bowling J. Melanotan-associated melanoma in situ. Australas J Dermatol. 2012;53:301–2.CrossRefPubMedGoogle Scholar
  65. 65.
    Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228:34–6.CrossRefPubMedGoogle Scholar
  66. 66.
    Reid C, Fitzgerald T, Fabre A, Kirby B. Atypical melanocytic naevi following melanotan injection. Ir Med J. 2013;106:148–9.PubMedGoogle Scholar
  67. 67.
    Ellis RA, Kirkham N, Seukeran D. Malignant melanoma in a user of melanotan I. BMJ. 2009;338:b566.CrossRefGoogle Scholar
  68. 68.
    Cardones AR, Grichnik JM. Alpha-melanocyte-stimulating hormone-induced eruptive nevi. Arch Dermatol. 2009;145:441–4.CrossRefPubMedGoogle Scholar
  69. 69.
    Cousen P, Colver G, Helbling I. Eruptive melanocytic naevi following melanotan injection. Br J Dermatol. 2009;161:707–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Langan EA, Ramlogan D, Jamieson LA, Rhodes LE. Change in moles linked to use of unlicensed “sun tan jab”. BMJ. 2009;338:b277.CrossRefPubMedGoogle Scholar
  71. 71.
    Sela M. Antigenicity: some molecular aspects. Science. 1969;166:1365–74.CrossRefPubMedGoogle Scholar
  72. 72.
    Mariani M, Bracci L, Presentini R, Nucci D, Neri P, Antoni G. Immunogenicity of a free synthetic peptide: carrier-conjugation enhances antibody affinity for the native protein. Mol Immunol. 1987;24:297–303.CrossRefPubMedGoogle Scholar
  73. 73.
    Spichty R, Balimann M, Barman J, Minder EI. A bioassay for detection of neutralizing antibodies against the alpha-melanocyte stimulating hormone analogue afamelanotide in patients with erythropoietic protoporphyria. J Pharm Biomed Analy. 2013;75:192–8.CrossRefGoogle Scholar
  74. 74.
    Lengweiler S, Kreim S, Barman-Aksozen J, Maurer M, Minder EI. Evaluation of the immunogenicity of the synthetic alpha-melanocyte-stimulating hormone (alpha-MSH) analogue afamelanotide ([Nle4-D-Phe7]-alpha-MSH, Scenesse®) in erythropoietic protoporphyria patients by ELISA detecting both anti-afamelanotide and anti-alpha-MSH antibodies. Skin Pharmacol Physiol. 2015;28:103–13.CrossRefPubMedGoogle Scholar
  75. 75.
    Fetissov SO, Harro J, Jaanisk M, Jarv A, Podar I, Allik J, et al. Autoantibodies against neuropeptides are associated with psychological traits in eating disorders. Proc Natl Acad Sci USA. 2005;102:14865–70.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Elisabeth I. Minder
    • 1
    Email author
  • Jasmin Barman-Aksoezen
    • 2
  • Xiaoye Schneider-Yin
    • 2
  1. 1.Stadtspital Triemli, Porphyria Outpatient ClinicsZurichSwitzerland
  2. 2.Stadtspital Triemli, Institute of Laboratory MedicineZurichSwitzerland

Personalised recommendations